Clinical Trial Update: 18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating 18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a biomarker for response to progesterone therapy in endometrial hyperplasia with at…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Endometrial Hyperplasia with Atypia

Drugs mentioned

• FFNP (18-fluorofuranylnorprogesterone) (18-fluorofuranylnorprogesterone)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Complex Atypical Hyperplasia, Endometrial Cancer | Phase 2 | Status: WITHDRAWN